Stay updated with breaking news from Tolerability Concerns. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Jane L. Meisel, MD, discusses the importance of prioritizing patients’ toxicity concerns and quality of life in the management of breast cancer.
Jane L. Meisel, MD, highlighted patient-reported gaps in provider communication regarding treatment-related toxicities in metastatic breast cancer.
Hepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation with Final Dose Cohort in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH - DSMB Recommended the AMBITION Study Continue with Final Dosing Cohort - - Final Cohort Expected to be Completed in Early 2021 - EDISON, NJ / ACCESSWIRE / December 29, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, "Hepion"), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatiti...